Akademik Veri Yönetim Sistemi
10th International Medicine and Health Sciences Researches Congress, Ankara, Türkiye, 27 - 28 Ağustos 2022, cilt.1, sa.359, ss.502-503, (Özet Bildiri)
Doxorubicin (DOX) is one of the most critical antitumor drugs. However, the clinical use of DOX has
been limited due to serious undesirable side effects in many organs. This study aimed to analyse the
effect of Selenium (Se) and N-(p-Amylcinnamoyl) Anthranilic Acid (ACA) on kidney tissue in DOXadministered rats. Rats were divided into six groups (n=10); Control, DMSO, DOX, DOX+Se,
DOX+ACA and DOX+Se+ACA. In the study, DOX (2.5 mg/kg dissolved in DMSO) was administered
to the rats intraperitoneally (i.p.) on days 2, 4, 6, 8, 10, 12, and 14 (The cumulative dose of DOX was
15 mg/kg throughout the study). Se dissolved in isotonic solution was applied as i.p. and 0.5 mg/kg dose
every day for 14 days. ACA dissolved in DMSO was applied as i.p. and 25 mg/kg daily for 14 days.
After 14 days of study, the rat’s intracardiac blood was taken, and kidney tissues were removed under
anaesthesia. Urea and creatinine levels were examined in serum samples. In addition, histopathological
examination determined H&E and 8-OHdG expression in kidney tissue was determined by
immunohistochemical analysis. After Se and ACA treatments, DOX-induced urea and creatine levels
were decreased in the rat serum (p≤0.05). In the group with DOX, glomerular atrophy, dilatation in
tubular and glomerular, congestion in vessels, and vocalisation in tubular epithelial cells were improved
to varying degrees in the treatment groups with Se and ACA. In addition, Se and ACA treatments
reduced the DOX-induced 8-OHdG expression (p≤0.05). These findings indicated that Se and ACA
might be used as important therapeutic agents to inhibit renal dysfunction and oxidative DNA damage
after DOX-induced kidney injury.